In 2025, the China National Medical Products Administration (NMPA) approved 289 new drug applications, encompassing a variety of chemical drugs, therapeutic biological products, and traditional Chinese medicines, as per the Provisions for Drug Registration 2020. Notably, this count excludes vaccines, biosimilars, and in vitro diagnostic reagents.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.nature.com/articles/d41573-026-00028-2
